Form 4: Allogene Therapeutics Director Arie Belldegrun Reports Share Acquisition and Option Grant

Director Arie Belldegrun of Allogene Therapeutics reports acquiring shares and stock options, while also disclosing indirect holdings through various entities.

Summary

• Arie Belldegrun, a director at Allogene Therapeutics, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• The filing shows the acquisition of 369,957 common shares at $0 price.
• Belldegrun also acquired 1,307,927 stock options with an exercise price of $1.94.
• The director's indirect holdings include 4,710,120 shares held by Bellco Legacy Trust, 1,798,163 shares held by Vida Ventures LLC, 1,724,137 shares held by Vida Ventures III, L.P. and Vida Ventures III-A, L.P., and 539,867 shares held by Bellco Legacy LLC.
• The stock options vest over time, with 25% vesting on January 24, 2026, and the remainder vesting monthly over the following 36 months.

Sentiment

Score: 7

Explanation: The document reflects standard insider transactions, which are generally viewed neutrally to slightly positive as they indicate confidence from a director. The acquisition of shares at no cost is a positive sign.

Positives

• The acquisition of shares and stock options by a director could be seen as a positive sign of confidence in the company's future.
• The vesting schedule of the stock options aligns the director's interests with the long-term performance of the company.

Risks

• The document primarily reflects changes in ownership and does not indicate any specific risks.
• The indirect holdings through various entities could make it difficult to track the director's actual stake in the company.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in the biotechnology industry where stock-based compensation is frequently used.

Comparison to Industry Standards

• Stock option grants and share acquisitions are standard practice for directors and executives in publicly traded biotech companies like Allogene.
• The vesting schedule of the stock options is typical, aligning with industry norms for incentivizing long-term performance.
• The use of trusts and investment vehicles for holding shares is also common among high-net-worth individuals and executives in the sector.

Stakeholder Impact

• The share acquisition and option grant could be viewed positively by shareholders as it aligns the director's interests with the company's performance.
• The transactions do not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Allogene Therapeutics, Arie Belldegrun, Form 4, Beneficial Ownership, Stock Options, Director, Share Acquisition, Indirect Holdings